- Home
- AEVA vs XERS Comparison
AEVA vs XERS Comparison
Compare AEVA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEVA | XERS |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | 276 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 965.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEVA | XERS |
|---|---|---|
| Price | $15.40 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $26.50 | $10.43 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $85.37 | $28.65 |
| Revenue Next Year | $132.72 | $18.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $2.64 | $3.81 |
| 52 Week High | $38.79 | $10.08 |
Technical Indicators
Market Signals| Indicator | AEVA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 26.28 |
| Support Level | $12.28 | $4.30 |
| Resistance Level | $18.19 | $5.49 |
| Average True Range (ATR) | 1.29 | 0.35 |
| MACD | 0.33 | -0.06 |
| Stochastic Oscillator | 55.53 | 3.34 |
Price Performance
Historical ComparisonAbout AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.